GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,463.00p
   
  • Change Today:
    -20.50p
  • 52 Week High: 1,812.50
  • 52 Week Low: 1,264.00
  • Currency: UK Pounds
  • Shares Issued: 4,110.44m
  • Volume: 5,518,193
  • Market Cap: £60,136m
  • RiskGrade: 129

GSK Overview

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.

1 Day Chart (01-05-2025)

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 4.2% 0.0%
Div Cover 2.6 2.6
Op Mrgn 12.8% 28.0%
ROCE 47.1%  
Latest F'cast
P/E 9.2 8.0
PEG 3.4 1.5
Pr/Revenue 1.9 1.7
Pr/Book 4.6  
Latest F'cast
Revenue 3.5% 4.1%
PBT -42.7% 163.4%
EPS 2.7% 4.6%
DPS 5.2% 305.3%

GSK Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-20 34,099.00 6,968.00 115.90p 14.5 n/a -6% 80.00p 4.8%
31-Dec-21 24,696.00 3,599.00 90.56p 22.2 n/a -22% 80.00p 4.0%
31-Dec-22 29,324.00 5,628.00 139.70p 10.3 0.2 +54% 44.00p 3.1%
31-Dec-23 30,328.00 6,064.00 155.10p 9.4 0.9 +11% 58.00p 4.0%
31-Dec-24 31,376.00 3,477.00 159.30p 8.5 2.8 +3% 61.00p 4.5%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

GSK Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-25 32,651.78 9,158.50 166.70p 8.8 1.9 +5% 64.85p 0.0%
31-Dec-26 34,394.17 10,086.39 185.50p 7.9 0.7 +11% 69.41p 0.0%
31-Dec-27 35,780.27 10,648.53 197.65p 7.4 1.1 +6% 73.31p 0.0%

Copyright © 2025 FactSet Research Systems Inc. All rights reserved.

GSK Company Announcements

Director/PDMR Shareholding 01-May-2025 15:30 RNS
Total Voting Rights 01-May-2025 15:00 RNS
Nucala MATINEE data in COPD published in NEJM 01-May-2025 07:00 RNS

GSK ShareCast News

GSK's Nucala delivers positive outcomes in publi... 01-May-2025 ShareCast
London close: Stocks finish higher as US economy... 30-Apr-2025 ShareCast
GSK confirms guidance after strong first quarter 30-Apr-2025 ShareCast

GSK Top Newspaper Links

GSK ‘well positioned’ to cope with US pharmaceut... 30-Apr-2025 Times
GlaxoSmithKline scraps sale of old drugs 05-Dec-2014 Telegraph
Glaxo sharpens axe to save £1bn as insurers and ... 01-Dec-2014 The Independent

Latest GSK Director Deals

Traded Action Notifier PriceAmountValue
16-Apr-25 Buy Dividends Julie Brown 1,275.00p 1,588 £20,247.00
16-Apr-25 Buy Dividends Emma Walmsley 1,275.00p 4,930 £62,857.50
11-Apr-25 Buy Vishal Sikka 1,304.95p 196 £2,557.70

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

GSK Market Data

Currency UK Pounds
Share Price 1,463.00p
Change Today -20.50p
% Change -1.38 %
52 Week High 1,812.50
52 Week Low 1,264.00
Volume 5,518,193
Shares Issued 4,110.44m
Market Cap £60,136m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
40.86% below the market average40.86% below the market average40.86% below the market average40.86% below the market average40.86% below the market average
4.17% above the sector average4.17% above the sector average4.17% above the sector average4.17% above the sector average4.17% above the sector average
Price Trend
21.07% above the market average21.07% above the market average21.07% above the market average21.07% above the market average21.07% above the market average
54.17% above the sector average54.17% above the sector average54.17% above the sector average54.17% above the sector average54.17% above the sector average
Income
70.61% above the market average70.61% above the market average70.61% above the market average70.61% above the market average70.61% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
42.3% below the market average42.3% below the market average42.3% below the market average42.3% below the market average42.3% below the market average
37.5% below the sector average37.5% below the sector average37.5% below the sector average37.5% below the sector average37.5% below the sector average

What The Brokers Say

Strong Buy 4
Buy 2
Neutral 15
Sell 3
Strong Sell 1
Total 25
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q1 Q4
Ex-Div 15-May-25 20-Feb-25
Paid 10-Jul-25 10-Apr-25
Amount 16.00p 16.00p

Trades for 01-May-2025

Time Volume / Share Price
16:22 0 @ 1,461.50p
16:08 1 @ 1,459.50p
16:08 2 @ 1,459.50p
15:36 1 @ 1,457.00p
15:33 0 @ 1,456.00p

GSK Key Personnel

CEO Emma Walmsley

Top of Page